Abstract
Purpose of Review
Stroke is a major health concern and a leading cause of long-term disability. Persistent post-stroke headache (PPSH) is a common complication of stroke yet little is known about its specific characteristics or optimal management. The purpose of this review is to discuss the epidemiology, presentation, and hypothesized pathophysiology of PPSH. Acute and preventive treatment options, as well as specific concerns regarding triptans and the newer CGRP antagonists, will be discussed in detail as well.
Recent Findings
The 2018 International Classification of Headache Disorders, 3rd edition (ICHD-3) was the first headache diagnostic manual to include criteria for PPSH and defines this disorder as an acute headache that develops in close temporal relation to stroke and persists beyond 3 months. Recent literature estimates the prevalence of PPSH to be somewhere between 1 and 23% of patients post-stroke. Presentation is variable, but most often mimics tension-type headache. There are no evidence-based guidelines on the optimal treatment of PPSH.
Summary
PPSH is a common but poorly understood complication of stroke. Given the significant disability burden that PPSH carries, the epidemiology and pathophysiology of PPSH, as well as the efficacy and safety of potential treatment options, warrant further investigation.
Similar content being viewed by others
Availability of Data and Materials
Not applicable.
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Stroke Facts | cdc.gov. https://www.cdc.gov/stroke/facts.htm. Accessed 23 May 2023.
Evans RW, Mitsias PD. Headache at onset of acute cerebral ischemia. Headache. 2009;49:902–8.
•• Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke. Neurology. 2020;94:e75–e86. A systematic review of 50 studies examining the prevalence and characteristics of new-onset post-stroke headache.
Olesen J. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
Lai J, Harrison RA, Plecash A, Field TS, Lai J, Plecash A, et al. A narrative review of persistent post-stroke headache–a new entry in the international classification of headache disorders, 3rd Edition. Headache. 2018;58:1442–53.
Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain. 2012;16:1128–36.
Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. Cephalalgia. 2015;35:399–409.
Carvalho Dias M, Martins T, Basílio G, Lucas Neto L, Caeiro L, Ferro JM, et al. Headache at the chronic stage of ischemic stroke. Headache. 2020;60:607–14.
•• Lebedeva ER, Ushenin AV, Gurary NM, Gilev DV, Kislyak NV, Olesen J. Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development. J Headache Pain. 2020;23:1–10. A prospective cohort study examining the prevalence, characteristics, and treatment of PPSH.
Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28:598–604.
Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–6.
Seifert CL, Schönbach EM, Magon S, Gross E, Zimmer C, Förschler A, et al. Headache in acute ischaemic stroke: a lesion mapping study. Brain. 2016;139:217–26.
Oliveira FAA, Sampaio Rocha-Filho PA. Headaches attributed to ischemic stroke and transient ischemic attack. Headache. 2019;59:469–76.
Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol. 2010. https://doi.org/10.3389/FNEUR.2010.00016.
Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) Study. Headache. 2019;59:32.
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–39.
Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60:649–53.
Leroux E, Rothrock J. Triptans for migraine patients with vascular risks: new insights, new options. Headache. 2019;59:1589–96.
Zebenholzer K, Gall W, Gleiss A, Pavelic AR, Wöber C. Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database–a cohort study. Headache. 2022;62:604–12.
Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, et al. Triptans and CGRP blockade–impact on the cranial vasculature. J Headache Pain. 2017;18:1–7.
Robblee J, Harvey LK. Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep. 2022;26:647–55.
Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88:771.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:E2211–21.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.
Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487–99.
Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–40.
Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–7.
Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1365–77.
Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241–54.
Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–25.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887–98.
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230–41.
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51–60.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:1–33.
Author information
Authors and Affiliations
Contributions
The authors confirm contribution to the paper as follows: M.C. and A.T. wrote the main manuscript text. M.C. prepared the tables. M.C. and A.T. reviewed the manuscript.
Corresponding author
Ethics declarations
Ethical Approval
Not applicable.
Conflict of Interest
Not applicable.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chan, M., Thaler, A. Post-stroke Headache. Curr Pain Headache Rep 27, 673–678 (2023). https://doi.org/10.1007/s11916-023-01169-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-023-01169-4